Top

Published in:

01-11-2011 | Nuclear Medicine

Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomas

Authors: Masatoyo Nakajo, Masayuki Nakajo, Atsushi Tani, Yoriko Kajiya, Shunji Shimaoka, Akio Matsuda, Tatsuyuki Nioh, Tohru Nihara, Toyokuni Suenaga, Sadao Tanaka, Hiroshi Shirahama, Michiyo Higashi, Chihaya Koriyama

Published in: European Radiology | Issue 11/2011

Abstract

Objectives

To correlate primary oesophageal squamous cell carcinoma (SCC) ¹⁸F-fluoro-deoxyglucose (FDG) uptake with pathological factors and examine its significance regarding choice of therapy.

Methods

We retrospectively examined the factors affecting visible and non-visible FDG uptake in 37 primary lesions in 32 oesophageal SCC patients who underwent PET/CT before oesophagectomy or endoscopic submucosal dissection (ESD). We divided the lesions into pathological depth invasion ≥sm2 oesophagectomy (n = 18) and ≤sm1 ESD (n = 19) indicated groups and compared the diagnostic accuracy of FDG-PET with that of endoscopic ultrasound (EUS) performed for 23 superficial lesions to discriminate between these groups.

Results

There were 17 visible and 20 non-visible lesions. The lesion visibility was significantly higher in the larger (≥40 mm), non-flat type, more deeply invaded, positive vascular invasion (P < 0.001 each), positive nodal metastasis (P = 0.04) and higher Glut-1 score (P = 0.005) tumour groups. When the visible and non-visible lesions indicated a need for oesophagectomy and ESD respectively, the sensitivity, specificity and accuracy of oesophagectomy were 94% (17/18), 100% (19/19) and 97% (36/37) and those of EUS were 75% (3/4), 79% (15/19) and 78% (18/23) respectively.

Conclusions

Primary lesion FDG visibility can be one of the indicators for choosing between oesophagectomy and ESD for resectable oesophageal SCCs.

Endo M, Kawano T (1997) Detection and classification of early squamous cell esophageal cancer. Dis Esophagus 10:155–158PubMed

Murata Y, Suzuki S, Ohta M et al (1996) Small ultrasonic probes for determination of the depth of superficial esophageal cancer. Gastrointest Endosc 44:23–28PubMedCrossRef

Kato H, Tachimori Y, Watanabe H, Yamaguchi H, Ishikawa T, Itabashi M (1990) Superficial esophageal carcinoma. Surgical treatment and the results. Cancer 66:2319–2323PubMedCrossRef

Kato H, Tachimori Y, Mizobuchi S, Igaki H, Ochiai A (1993) Cervical, mediastinal, and abdominal lymph node dissection (three-field dissection) for superficial carcinoma of the thoracic esophagus. Cancer 72:2879–2882PubMedCrossRef

Fujita H, Sueyoshi S, Yamana H et al (2001) Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy. World J Surg 25:424–431PubMedCrossRef

Shimizu Y, Tsukagoshi H, Fujita M, Hosokawa M, Kato M, Asaka M (2002) Long-term outcome after endoscopic mucosal resection in patients with esophageal squamous cell carcinoma invading the muscularis mucosae or deeper. Gatrointest Endosc 56:387–390CrossRef

Fujishiro M, Yahagi N, Kakushima N et al (2006) Endoscopic submucosal dissection of esophageal squamous cell neoplasms. Clin Gastroenterol Hepatol 4:688–694PubMedCrossRef

Himeno S, Yasuda S, Shimada H, Tajima T, Makuuchi H (2002) Evaluation of esophageal cancer by positron emission tomography. Jpn J Clin Oncol 32:340–346PubMedCrossRef

Kato H, Miyazaki T, Nakajima M et al (2005) The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 103:148–156PubMedCrossRef

10.

Hsu WH, Hsu PK, Wang SJ et al (2009) Positron emission tomography-computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma. Ann Thorac Surg 87:1564–1568PubMedCrossRef

11.

van Westreenen HL, Westreterp M, Bossuyt PM et al (2004) Systemic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22:3805–3812PubMedCrossRef

12.

van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD (2008) Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 98:547–557PubMedCrossRef

13.

Kato H, Kuwano H, Nakajima M et al (2002) Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94:921–928PubMedCrossRef

14.

Rizk N, Downey RJ, Akhurst T et al (2006) Preoperative 18[F]-fluoro-deoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg 81:1076–1081PubMedCrossRef

15.

Cerfolio RJ, Bryant AS (2006) Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 82:391–395PubMedCrossRef

16.

Chung HW, Lee KH, Lee EJ et al (2008) Comparison of uptake characteristics and prognostic value of ²⁰¹Tl and ¹⁸F-FDG in esophageal cancer. World J Surg 32:69–75PubMedCrossRef

17.

Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Kuwano H (2004) Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg 91:1004–1009PubMedCrossRef

18.

Guo H, Zhu H, Xi Y et al (2007) Diagnostic and prognostic value of ¹⁸F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med 48:1251–1258PubMedCrossRef

19.

Brücher BL, Weber W, Bauer M et al (2001) Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233:300–309PubMedCrossRef

20.

Downey RJ, Akhrust T, Ilson D et al (2003) Whole body ¹⁸FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21:428–432PubMedCrossRef

21.

Miyata H, Doki Y, Yasuda T et al (2008) Evaluation of clinical significance of ¹⁸F-fluorodeoxyglucose positron emission tomography in superficial squamous cell carcinomas of the thoracic esophagus. Dis Esophagus 21:144–150PubMedCrossRef

22.

Little SG, Rice TW, Bybel B et al (2007) Is FDG-PET indicated for superficial esophageal cancer? Eur J Cardiothorac Surg 31:791–796PubMedCrossRef

23.

Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG et al (2002) Esophagus. In: American Joint Committee on Cancer (AJCC) cancer staging manual. 6th ed. Springer-Verlag, New York, p 91–8

24.

Society JE, President Takubo K (2009) Japanese classification of esophageal cancer, tenth edition, part 1. Esophagus 6:1–25CrossRef

25.

Hiyoshi Y, Watanabe M, Imamura Y et al (2009) The relationship between the glucose transporter type 1 expression and ¹⁸F-fluorodeoxyglucose uptake in esophageal squamous cell carcinoma. Oncology 76:286–292PubMedCrossRef

26.

Japanese Society for Esophageal Diseases. President Isono K. The Japanese Esophageal Society (2002) guidelines for the treatment of esophageal cancer, Tokyo, Kanehara& Co., Ltd, 2002 [Japanese]

27.

Neto C, Zhuang H, Ghesani N, Alavi A (2001) Detection of Barrett’s esophagus superimposed by esophageal cancer by FDG positron emission tomography. Clin Nucl Med 26:1060PubMedCrossRef

28.

Roedl JB, Colen RR, King K, Fischman AJ, Mueller PR, Blake MA (2008) Visual PET/CT scoring for nonspecific ¹⁸F-FDG uptake in the differentiation of early malignant and benign esophageal lesions. AJR Am J Roentgenol 191:515–521PubMedCrossRef

29.

Tohma T, Okazumi S, Makino H et al (2005) Relationship between glucose transporter, and hexokinase and FDG-PET in esophageal cancer. Hepatogastroenterology 52:486–490PubMed

30.

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T (1992) Intratumoral distribution of fluorine-18-fuluolodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33:1972–1980PubMed

31.

Hubner KF, McDonald TW, Niethammer JG, Smith GT, Gould HR, Buonocore E (1993) Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[¹⁸F]deoxyglucose (2-[¹⁸F]FDG). Gynecol Oncol 51:197–204PubMedCrossRef

32.

Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ (1994) The dose uptake ratio as an index of glucose metabolism: useful parameter of oversimplification? J Nucl Med 35:1308–1312PubMed

33.

Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N (1995) High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 36:1301–1306PubMed

34.

Gupta N, Gill H, Graeber G, Bishop H, Hurst J, Stephens T (1998) Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest 114:1105–1111PubMedCrossRef

35.

Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’Doherty MJ, Smith MA (1999) A PET study of ¹⁸FDG in soft tissue masses. Eur J Nucl Med 26:22–30PubMedCrossRef

36.

Boerner AR, Weckesser M, Herzog H et al (1999) Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 26:226–230PubMedCrossRef

37.

Hustinx R, Smith RJ, Benard F et al (1999) Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 26:1345–1348PubMedCrossRef

38.

Kubota K, Itoh M, Ozaki K et al (2001) Advantage of delayed whole-body FDG-PET imaging for tomour detection. Eur J Nucl Med 28:696–703PubMedCrossRef

39.

Zhuang H, Pourdehnad M, Lambright ES et al (2001) Dual time point ¹⁸F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42:1412–1417PubMed

40.

Xiu Y, Bhutani C, Dhurairaj T et al (2007) Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 32:101–105PubMedCrossRef

41.

Chen CJ, Lee BF, Yao WJ et al (2008) Dual-phase ¹⁸F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol 191:475–479PubMedCrossRef

42.

Shinya T, Rai K, Okumura Y et al (2009) Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer. Clin Nucl Med 34:216–221PubMedCrossRef

43.

Suga K, Kawakami Y, Hiyama A, Matsunaga N (2009) Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan. Ann Nucl Med 23:399–407PubMedCrossRef

44.

Suga K, Kawakami Y, Hiyama A et al (2009) Dual-time point ¹⁸F-FDG PET/CT scan for differentiation between ¹⁸F-FDG-avid non-small cell lung cancer and benign lesions. Ann Nucl Med 23:427–435PubMedCrossRef

45.

Suga K, Kawakami Y, Hiyama A et al (2009) Differential diagnosis between ¹⁸F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan. Ann Nucl Med 23:523–531PubMedCrossRef

46.

Hu Q, Wang W, Zhong X et al (2009) Dual-time-point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer. Eur J Radiol 70:320–324PubMedCrossRef

47.

Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E, Ebied O (2009) Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT. Eur J Radiol 70:530–538PubMedCrossRef

48.

D’Souza MM, Marwaha RK, Sharma R et al (2010) Prospective evaluation of solitary thyroid nodule on 18F-FDG PET/CT and high-resolution ultrasonography. Ann Nucl Med 24:345–355PubMedCrossRef

49.

Cloran FJ, Banks KP, Song WS, Kim Y, Bradley YC (2010) Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity. Lung Cancer 68:66–71PubMedCrossRef

50.

Lan XL, Zhang YX, Wu ZJ, Jia Q, Wei H, Gao ZR (2008) The value of dual time point ¹⁸F-FDG PET imaging for the differentiation between malignant and benign lesions. Clin Radiol 63:756–764PubMedCrossRef

51.

Uesaka D, Demura Y, Ishizaki T et al (2008) Evaluation of dual-time-point ¹⁸F-FDG PET for staging in patients with lung cancer. J Nucl Med 49:1606–1612PubMedCrossRef

52.

Inoue A, Tomiyama N, Tatsumi M et al (2009) ¹⁸F-FDG PET for the evaluation of thymic epithelial tumors: correlation with the World Health Organization classification in addition to dual-time-point imaging. Eur J Nucl Med Mol Imaging 36:1219–1225PubMedCrossRef

53.

Caprio MG, Cangiano A, Imbriaco M et al (2010) Dual-time-point [¹⁸F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions. Radiol Med 115:215–224PubMedCrossRef

54.

MacDonald K, Searle J, Lyburn I (2011) The role of dual time point FDG PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake less than 2.5. Clin Radiol 66:244–250PubMedCrossRef

55.

Nakamoto Y, Higashi T, Sakahara H et al (2000) Delayed ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 89:2547–2554PubMedCrossRef

56.

Van Westreenen HL, Plukker JT, Cobben DC, Verhoogt CJ, Groen H, Jager PL (2005) Prognostic value of the standardized uptake value in esophageal cancer. AJR Am J Roentgenol 185:436–440PubMed

57.

Yamamoto H (2007) Technology insight: endoscopic submucosal dissection of gastrointestinal neoplasms. Nat Clin Pract Gastroenterol Hepatol 4:511–520PubMedCrossRef

58.

Eguchi T, Nakanishi Y, Shimoda T et al (2006) Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of 464 surgically resected cases. Mod Pathol 19:475–480PubMedCrossRef

59.

Endo M, Yoshino K, Kawano T, Nagai K, Inoue H (2000) Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus. Dis Esophagus 13:125–129PubMedCrossRef

60.

Puli SR, Reddy JB, Bechtold ML, Antillon D, Ibdah JA, Antillon MR (2008) Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systemic review. World J Gastroenterol 14:1479–1490PubMedCrossRef

61.

Seewald S, Ang TL, Soehendra N (2007) Radial EUS: the clinical impact of T staging. Minerva Med 98:305–311PubMed

62.

Rampado S, Bocus P, Battaglia G, Ruol A, Portale G, Ancona E (2008) Endoscopic ultrasound: accuracy in staging superficial carcinomas of the esophagus. Ann Thorac Surg 85:251–256PubMedCrossRef

Title: Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomas
Authors: Masatoyo Nakajo
Masayuki Nakajo
Atsushi Tani
Yoriko Kajiya
Shunji Shimaoka
Akio Matsuda
Tatsuyuki Nioh
Tohru Nihara
Toyokuni Suenaga
Sadao Tanaka
Hiroshi Shirahama
Michiyo Higashi
Chihaya Koriyama
Publication date: 01-11-2011
Publisher: Springer-Verlag
Published in: European Radiology / Issue 11/2011
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-011-2196-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomas

Abstract

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2011

Does the degree of background enhancement in breast MRI affect the detection and staging of breast cancer?

Reply to letter to the editor re: contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100)

A method of adjusting SUV for injection-acquisition time differences in 18 F-FDG PET Imaging

Gd-EOB-DTPA-enhanced 3.0 T MR imaging: quantitative and qualitative comparison of hepatocyte-phase images obtained 10 min and 20 min after injection for the detection of liver metastases from colorectal carcinoma

Extra-mammary findings in breast MRI

Letter to the editor re: contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100)